Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study

Cancer ◽  
2014 ◽  
Vol 121 (3) ◽  
pp. 423-431 ◽  
Author(s):  
Jorge J. Castillo ◽  
Mark Bower ◽  
Jérémy Brühlmann ◽  
Urban Novak ◽  
Hansjakob Furrer ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Prognostic Factors ◽  
Retrospective Study ◽  
Antiretroviral Therapy ◽  
Hodgkin Lymphoma ◽  
Advanced Stage ◽  
Classical Hodgkin Lymphoma ◽  
Immunodeficiency Virus ◽  
Combined Antiretroviral Therapy

scholarly journals Symptoms of Autonomic Dysfunction in Human Immunodeficiency Virus

2015 ◽  
Vol 2 (3) ◽  
Author(s):  
Dominic Chow ◽  
Beau K. Nakamoto ◽  
Katherine Sullivan ◽  
David M. Sletten ◽  
Satomi Fujii ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Retrospective Study ◽  
Antiretroviral Therapy ◽  
Sexual Dysfunction ◽  
Autonomic Dysfunction ◽  
Immunodeficiency Virus ◽  
Combined Antiretroviral Therapy ◽  
Male Sexual Dysfunction ◽  
Hiv Negative

Abstract This retrospective study evaluated the frequencies of symptoms associated with autonomic dysfunction in human immunodeficiency virus (HIV)-infected patients on stable combined antiretroviral therapy. Patients infected with HIV reported higher frequencies of dysautonomia symptoms compared with HIV-negative patients, particularly in the autonomic domains related to urinary, sleep, gastroparesis, secretomotor, pupillomotor, and male sexual dysfunction.

Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus

Cancer ◽  
2000 ◽  
Vol 88 (7) ◽  
pp. 1696-1702 ◽  
Author(s):  
Frantz Thiessard ◽  
Philippe Morlat ◽  
Catherine Marimoutou ◽  
Eric Labouyrie ◽  
Jean-Marie Ragnaud ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Prognostic Factors ◽  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Immunodeficiency Virus

The role of the microenvironment in human immunodeficiency virus-associated classical Hodgkin lymphoma

2014 ◽  
Vol 65 (6) ◽  
pp. 749-756 ◽  
Author(s):  
Athanasios Koulis ◽  
Pritesh Trivedi ◽  
Hazem Ibrahim ◽  
Mark Bower ◽  
Kikkeri N Naresh
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hodgkin Lymphoma ◽  
Classical Hodgkin Lymphoma ◽  
Immunodeficiency Virus

Analysis of prognostic factors in childhood advanced stage Hodgkin lymphoma: A retrospective study.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e21000-e21000 ◽  
Author(s):  
Amol Shankar Dongre ◽  
Brijesh Arora ◽  
Shripad Dinanath Banavali ◽  
Seema Gulia ◽  
Siddarth Laskar ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Retrospective Study ◽  
Hodgkin Lymphoma ◽  
Advanced Stage

scholarly journals Evaluation of Kidney Function Tests in HIV-Positive Patients Receiving Combined Antiretroviral Therapy

2021 ◽  
Author(s):  
emre aydın ◽  
Fatma Yılmaz Aydın ◽  
Yakup Demir ◽  
Yaşar Yıldırım ◽  
Mustafa Kemal Çelen
Keyword(s):  
Human Immunodeficiency Virus ◽  
Glomerular Filtration Rate ◽  
Antiretroviral Therapy ◽  
Filtration Rate ◽  
Estimated Glomerular Filtration Rate ◽  
Hiv Positive ◽  
Group 4 ◽  
Immunodeficiency Virus ◽  
Combined Antiretroviral Therapy ◽  
Group 5

Introduction: Human Immunodeficiency virus is a chronic infection that attacks the immune system of the human body, particularly CD4 T lymphocytes. Combined antiretroviral therapies are highly effective in virological suppression of human immunodeficiency virus infection. It has been shown that some retroviral therapies have a higher nephrotoxicity potential. As a result of renal injury, serum creatinine increases, and the estimated glomerular filtration rate is reduced. The aim of our study was to assess changes in kidney function during a 24-month period in HIV-positive patients who were begun on combined antiretroviral therapy. Material-method: A total of 127 HIV positive patients were enrolled. The patients were divided into five groups; patients who received no therapy were designated as Group 1; those that received Dolutegravir/Abacavir/Lamivudine combination as Group 2; those that received Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate combination as Group 3; those that received Emtricitabine/Tenofovir Disoproxil Fumarate/Dolutegravir combination as Group 4; and those that received Emtricitabine/Tenofovir Disoproxil Fumarate/Raltegravir combination as Group 5. We compared the effects of these drugs on estimated glomerular filtration rate during a 24-month follow-up period. Results: At the 24th month of therapy, a significant difference was observed between the eGFR levels of the study groups (p:<0.001). eGFR level was significantly higher in Group 4 compared to Groups 1, 2, and 3 (p:0.009, p:<0.001, p:<0.001, respectively) while it was significantly lower in Group 5 than groups 1, 2, and 3 (p:0.005, p:<0.001, p:<0.001, respectively). No significant eGFR difference was found between Group 4 and Group 5 (p>0.05). Serum creatinine level was significantly higher in Groups 4 and 5 compared to the other groups (p<0.001). Conclusion: The use of TDF-containing regimens causes renal dysfunction. Therefore, we recommend close monitoring of renal function, especially in patients treated with TDF.

Sign in / Sign up

Export Citation Format

Share Document